A phase 2 efficacy and safety study of SU011248 [sunitinib] administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma.

Trial Profile

A phase 2 efficacy and safety study of SU011248 [sunitinib] administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 22 Oct 2015 Post hoc pooled analysis results published in the British Journal of Cancer
    • 03 Jul 2013 New source identified and integrated (German Clinical Trials Register, DRKS00004029).
    • 14 Apr 2009 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top